

AREVOLUTION INJOINT CARE



4CYTE™ Epiitalis® Forte Horse has been scientifically proven to enhance joint health and function in horses.



What is Epiitalis®?

Derived from a plant seed oil comprised of fatty acids, Epiitalis® is the world-exclusive active ingredient powering 4CYTE™. Epiitalis® is globally patented for its ability to help maintain healthy cartilage growth.









Why horse owners love 4CYTE™ Epiitalis® Forte Horse

- Supports normal joint function, mobility and flexibility
- Eases joint stiffness due to normal daily exercise and activity
- Helps maintain healthy cartilage development
- Helps maintain the health& resiliency of joints and connective tissue
- May help address occasional gait irregularity& unwillingness to travel forward
- Helps maintain a normal inflammatory response





Frequently Asked Questions

What flavor is 4CYTE™ Epiitalis® Forte Horse?

4CYTE™ Epiitalis® Forte Horse is a pleasant apple flavor.

How should 4CYTE™ Epiitalis® Forte Horse be administered?

Massage pouch well before each use. Follow the administration guide and draw an accurate volume of suspension from the pack using the applicator supplied. Administer orally.

Is a loading period required for 4CYTE™ Epiitalis® Forte Horse?

If the horse is showing signs of joint discomfort, has been diagnosed with osteoarthritis by a veterinarian or has recently undergone orthopaedic surgery, we recommend a two-week loading period.

Do I need to refrigerate the pouch?

No, refrigeration is not necessary although we do recommend to store at room temperature.

Is 4CYTE™ Epiitalis® Forte Horse suitable for use in breeding Stallions, pregnant or brood mares?

Effects on fertility or full term pregnancy has not been established. Refer to your vet for a risk/benefit assessment.

What if I miss a day?

Continue your usual volume the following day.

What age can I commence 4CYTE™ Epiitalis® Forte?

4CYTE™ Epiitalis® Forte Horse can be introduced to weanlings from 6 months of age.



*Volumes per 1,323 lbs horse

8.45 fl oz lasts approx. 63 days on a maintenance volume. **33.81** fl oz lasts approx. 250 days on a maintenance volume.

Loading Amount 8ml (0.271 fl oz) For 14 days Maintenance Amount 4ml (0.135 fl oz) Daily

Administer orally. Consult your veterinarian before using this product.

Massage pouch well before each use.



Active Ingredient

✓ Epiitalis®

Nutritional Information

Composition	Per 0.135 fl oz	Per 3.381 fl oz
Crude protein	4.23mg	0.10g
Carbohydrate	80mg	21.1g
Total fat	3.8g	93.33g
Energy kj	141.9kj	3488.54kj
Potassium	11.6mg	0.29g
Sodium	179mg	4.48g
Total omega-3 fatty acids	0.54g	13.54g
Total omega-6 fatty acids	1.83g	45.83g

Inactive Ingredients

Soya bean oil, nature identical apple flavor, natural sweetener - thaumatin, silica (natural thickener)







4CYTE™ Epiitalis® Forte Equine Clinical Trial

(Colorado State University) Published Frontiers of Veterinary Science, 2022

Radiographic evaluations were performed at baseline, day 14 and day 70. Significantly improved radiographic scores in Epiitalis® treated horses were observed for subchondral bone lysis of the radial carpal bone (p = 0.019), osteophyte formation (p < 0.001), subchondral sclerosis of the radial carpal bone (p = 0.012), and total radiographic score (p = 0.001) (Figure 1).

At endpoint, the total radiographic score of Epiitalis® treated horses was 63% lower than placebo treated horses (2.38 vs. 6.37, respectively).

The improvements observed in radiographic outcome parameters is strongly supportive of a disease-modifying effect with Epiitalis® treatment.




Figure 1. Dorsolatero-palmaromedial oblique radiographs of a placebo treated horse (A) and an Epiitalis® treated horse (B) on Day 70.

Osteochondral fragment visible in both horses. Sclerosis of third carpal bone and radiocarpal bone are visible in placebo-treated horse as well as enthesopathy of the joint capsule, and osteophytosis. Soft tissue swelling representing middle carpal joint effusion is the only common abnormality between the two horses.

This study adds to the growing body of evidence that supports the efficacy of Epiitalis® in effectively managing symptoms and slowing disease progression in horses with joint conditions such as osteoarthritis.

Synovial Fluid – PGE2

A significant reduction in the inflammatory marker PGE2 in the synovial fluid was observed in horses treated with Epiitalis® compared to placebo when analysed across the entire time course (p = 0.043, Figure 2).

The reduction of PGE2 concentration in synovial fluid demonstrates that Epiitalis® is acting to chronically reduce inflammation in the local joint environment.




Figure 2. Mean differences from baseline in PGE2 values for placebo and Epiitalis® treated horses, as a function of time.

